Latest Breaking News On - Oncology program dana farber brigham - Page 1 : comparemela.com

TMCnet News SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast [December 11, 2020] SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast – Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment – – Statistically Significant Difference of Duration of Immune Response of NPS vs. Control: p=0.000094 -    – Data to be Presented Today at the San Antonio Breast Cancer Symposium - NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, announced today final data with up to 6 months follow-up from a Phase 2 randomiz

United statesSan antonioAdam holdsworthAnnee osheaElizabetha mittendorfAngelosm stergiouLife sciences group incOncology program dana farber brighamNational cancer instituteWomen cancer centerMemorial sloan kettering cancer centerPositive follow up dataRandomized phaseDuctal carcinoma in situImmune stimulation augmentedStatistically significant difference